NuPathe submits Zelrix NDA to treat migraine

NuPathe Inc. (NASDAQ:PATH) submitted an NDA to FDA for Zelrix (formerly NP101) to treat migraine. Zelrix is a transdermal patch delivering sumatriptan via iontophoresis. NuPathe was down $0.11 to $6.1...